Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

53 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer's disease immunotherapeutics.
Goure WF, Krafft GA, Jerecic J, Hefti F. Goure WF, et al. Among authors: krafft ga. Alzheimers Res Ther. 2014 Jul 9;6(4):42. doi: 10.1186/alzrt272. eCollection 2014. Alzheimers Res Ther. 2014. PMID: 25045405 Free PMC article. Review.
An acute functional screen identifies an effective antibody targeting amyloid-β oligomers based on calcium imaging.
Wang X, Kastanenka KV, Arbel-Ornath M, Commins C, Kuzuya A, Lariviere AJ, Krafft GA, Hefti F, Jerecic J, Bacskai BJ. Wang X, et al. Among authors: krafft ga. Sci Rep. 2018 Mar 15;8(1):4634. doi: 10.1038/s41598-018-22979-2. Sci Rep. 2018. PMID: 29545579 Free PMC article.
The case for soluble Aβ oligomers as a drug target in Alzheimer's disease.
Hefti F, Goure WF, Jerecic J, Iverson KS, Walicke PA, Krafft GA. Hefti F, et al. Among authors: krafft ga. Trends Pharmacol Sci. 2013 May;34(5):261-6. doi: 10.1016/j.tips.2013.03.002. Epub 2013 Apr 10. Trends Pharmacol Sci. 2013. PMID: 23582316
Discovery of ADDL--targeting small molecule drugs for Alzheimer's disease.
Look GC, Jerecic J, Cherbavaz DB, Pray TR, Breach JC, Crosier WJ, Igoudin L, Hironaka CM, Lowe RM, McEntee M, Ruslim-Litrus L, Wu HM, Zhang S, Catalano SM, Goure WF, Summa D, Krafft GA. Look GC, et al. Among authors: krafft ga. Curr Alzheimer Res. 2007 Dec;4(5):562-7. doi: 10.2174/156720507783018271. Curr Alzheimer Res. 2007. PMID: 18220523 Review.
ADDLs and the signaling web that leads to Alzheimer's disease.
Krafft GA, Klein WL. Krafft GA, et al. Neuropharmacology. 2010 Sep-Oct;59(4-5):230-42. doi: 10.1016/j.neuropharm.2010.07.012. Epub 2010 Jul 23. Neuropharmacology. 2010. PMID: 20650286 Review.
Days to criterion as an indicator of toxicity associated with human Alzheimer amyloid-beta oligomers.
Gandy S, Simon AJ, Steele JW, Lublin AL, Lah JJ, Walker LC, Levey AI, Krafft GA, Levy E, Checler F, Glabe C, Bilker WB, Abel T, Schmeidler J, Ehrlich ME. Gandy S, et al. Among authors: krafft ga. Ann Neurol. 2010 Aug;68(2):220-30. doi: 10.1002/ana.22052. Ann Neurol. 2010. PMID: 20641005 Free PMC article.
Synaptic targeting by Alzheimer's-related amyloid beta oligomers.
Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, Lambert MP, Velasco PT, Bigio EH, Finch CE, Krafft GA, Klein WL. Lacor PN, et al. Among authors: krafft ga. J Neurosci. 2004 Nov 10;24(45):10191-200. doi: 10.1523/JNEUROSCI.3432-04.2004. J Neurosci. 2004. PMID: 15537891 Free PMC article.
Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss.
Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, Krafft GA, Klein WL. Gong Y, et al. Among authors: krafft ga. Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10417-22. doi: 10.1073/pnas.1834302100. Epub 2003 Aug 18. Proc Natl Acad Sci U S A. 2003. PMID: 12925731 Free PMC article.
Selective neuronal degeneration induced by soluble oligomeric amyloid beta protein.
Kim HJ, Chae SC, Lee DK, Chromy B, Lee SC, Park YC, Klein WL, Krafft GA, Hong ST. Kim HJ, et al. Among authors: krafft ga. FASEB J. 2003 Jan;17(1):118-20. doi: 10.1096/fj.01-0987fje. Epub 2002 Nov 1. FASEB J. 2003. PMID: 12424218
Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies.
Lambert MP, Viola KL, Chromy BA, Chang L, Morgan TE, Yu J, Venton DL, Krafft GA, Finch CE, Klein WL. Lambert MP, et al. Among authors: krafft ga. J Neurochem. 2001 Nov;79(3):595-605. doi: 10.1046/j.1471-4159.2001.00592.x. J Neurochem. 2001. PMID: 11701763
53 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback